EA202192327A1 - T-клеточные рецепторы, специфичные к mage-a4 - Google Patents

T-клеточные рецепторы, специфичные к mage-a4

Info

Publication number
EA202192327A1
EA202192327A1 EA202192327A EA202192327A EA202192327A1 EA 202192327 A1 EA202192327 A1 EA 202192327A1 EA 202192327 A EA202192327 A EA 202192327A EA 202192327 A EA202192327 A EA 202192327A EA 202192327 A1 EA202192327 A1 EA 202192327A1
Authority
EA
Eurasian Patent Office
Prior art keywords
tcr
mage
cell receptors
receptors specific
provides
Prior art date
Application number
EA202192327A
Other languages
English (en)
Inventor
Кристиан Эллингер
Даниэль Зоммермайер
Джеффри Блекберн Парсонс
Джасдип МАНН
Original Assignee
Медиджен Иммьюнотерапис Гмбх
2Севенти Био, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Медиджен Иммьюнотерапис Гмбх, 2Севенти Био, Инк. filed Critical Медиджен Иммьюнотерапис Гмбх
Publication of EA202192327A1 publication Critical patent/EA202192327A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Abstract

В соответствии с настоящим изобретением предложен выделенный T-клеточный рецептор (TCR), специфичный к MAGE-A4, и полипептид, содержащий функциональную часть TCR. Дополнительно предложены поливалентный комплекс TCR, нуклеиновая кислота, кодирующая TCR, клетка, экспрессирующая TCR, и фармацевтическая композиция, содержащая TCR. В соответствии с настоящим изобретением также предложен TCR для применения в качестве лекарственного средства, в частности TCR для применения для лечения рака.
EA202192327A 2019-03-27 2020-03-27 T-клеточные рецепторы, специфичные к mage-a4 EA202192327A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19165387.2A EP3714941A1 (en) 2019-03-27 2019-03-27 Mage-a4 tcrs
PCT/EP2020/058779 WO2020193767A1 (en) 2019-03-27 2020-03-27 Mage a4 t cell receptors

Publications (1)

Publication Number Publication Date
EA202192327A1 true EA202192327A1 (ru) 2022-01-19

Family

ID=66000958

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202192327A EA202192327A1 (ru) 2019-03-27 2020-03-27 T-клеточные рецепторы, специфичные к mage-a4

Country Status (15)

Country Link
US (1) US20230159612A1 (ru)
EP (2) EP3714941A1 (ru)
JP (1) JP2022527635A (ru)
KR (1) KR20210150440A (ru)
CN (1) CN114126716A (ru)
AU (1) AU2020249598A1 (ru)
BR (1) BR112021019066A2 (ru)
CA (1) CA3134076A1 (ru)
CL (1) CL2021002491A1 (ru)
CO (1) CO2021012587A2 (ru)
EA (1) EA202192327A1 (ru)
IL (1) IL286569A (ru)
MX (1) MX2021011613A (ru)
SG (1) SG11202110171QA (ru)
WO (1) WO2020193767A1 (ru)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3139011A1 (en) * 2019-05-08 2020-11-12 Medigene Immunotherapies Gmbh Engineered t cells
BR112022019380A2 (pt) * 2020-03-27 2022-11-29 2Seventy Bio Inc Receptores de células t
CN111647069B (zh) * 2020-06-17 2022-06-21 深圳豪石生物科技有限公司 一种改进的tcr及其应用
CA3210289A1 (en) 2021-03-09 2022-09-15 Anna Maria SOBIERAJ Mage-a4 peptide-mhc antigen binding proteins
CN115975003B (zh) * 2021-03-09 2024-01-26 科士华(南京)生物技术有限公司 Tcr、多肽、表达载体、宿主细胞、药物组合物和tcr获得方法
EP4091627A1 (en) 2021-05-21 2022-11-23 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Tcr constructs specific for magea4-derived epitopes
CN117980326A (zh) 2021-07-14 2024-05-03 2赛文缇生物公司 与来自抗体的结合结构域融合的经工程化的t细胞受体
CN116836261A (zh) * 2022-03-24 2023-10-03 香雪生命科学技术（广东）有限公司 一种识别mage-a4抗原的高亲和力tcr及其序列和应用
WO2023196996A2 (en) 2022-04-08 2023-10-12 2Seventy Bio, Inc. Multipartite receptor and signaling complexes
WO2023230512A1 (en) 2022-05-26 2023-11-30 2Seventy Bio, Inc. Compositions for maintaining lentiviral vector and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4703004A (en) 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide
US4851341A (en) 1986-12-19 1989-07-25 Immunex Corporation Immunoaffinity purification system
PT1421115E (pt) 2001-08-31 2005-07-29 Avidex Ltd Receptor de celulas t soluvel
EP2006376A1 (en) 2007-06-21 2008-12-24 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH Fusion protein comprising a caspase domain and a nuclear hormone receptor binding domain and methods and uses thereof
KR102480188B1 (ko) * 2012-09-14 2022-12-21 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 Mhc ii형 제한된 mage-a3을 인식하는 t 세포 수용체
PL3440106T3 (pl) * 2016-04-08 2022-01-31 Adaptimmune Limited Receptory występujące na limfocytach t
HUE059159T2 (hu) * 2016-04-08 2022-10-28 Immunocore Ltd T-sejt-receptorok
AU2018318303A1 (en) * 2017-08-18 2020-04-09 Gritstone Bio, Inc. Antigen-binding proteins targeting shared antigens

Also Published As

Publication number Publication date
KR20210150440A (ko) 2021-12-10
MX2021011613A (es) 2021-12-15
BR112021019066A2 (pt) 2021-11-30
IL286569A (en) 2021-12-01
US20230159612A1 (en) 2023-05-25
SG11202110171QA (en) 2021-10-28
CA3134076A1 (en) 2020-10-01
EP3714941A1 (en) 2020-09-30
WO2020193767A1 (en) 2020-10-01
CO2021012587A2 (es) 2022-02-28
JP2022527635A (ja) 2022-06-02
EP3946621A1 (en) 2022-02-09
CL2021002491A1 (es) 2022-06-10
CN114126716A (zh) 2022-03-01
AU2020249598A1 (en) 2021-10-28

Similar Documents

Publication Publication Date Title
EA202192327A1 (ru) T-клеточные рецепторы, специфичные к mage-a4
EA202092032A1 (ru) Т-клеточный рецептор, специфичный в отношении ny-eso-1/lage-1, и его применения
AU2021203746B2 (en) T cell receptors recognizing MHC class II-restricted MAGE-A3
EA201991696A1 (ru) Т-клеточные рецепторы, связывающиеся с ny-eso-1, и способы их применения
BR112016027805A2 (pt) receptores de células t do anti-papilomavírus humano 16 e7
PH12021550307A1 (en) T Cell Receptor Constructs And Uses Thereof
EA202191107A1 (ru) T-клеточные рецепторы ny-eso-1 и способы их применения
BR112019007100A2 (pt) composições e métodos para reprogramação de receptores de célula t com o uso de proteínas de fusão
EA202091335A1 (ru) Ограниченные hla класса i t-клеточные рецепторы против мутантного ras
EA201792420A1 (ru) Композиции и способы перепрограммирования tcr с помощью гибридных белков
EA202192726A1 (ru) Magea1-специфические т-клеточные рецепторы и их использование
EA202090652A1 (ru) T-клеточные рецепторы, рестриктированные по антигену лейкоцитов человека класса ii, против мутантного ras
EA201992063A1 (ru) СВЯЗЫВАЮЩИЕ ErbB-2 И ErbB-3 БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА ДЛЯ ПРИМЕНЕНИЯ ДЛЯ ЛЕЧЕНИЯ КЛЕТОК, КОТОРЫЕ СОДЕРЖАТ СЛИТЫЙ ГЕН NRG-1
PE20200152A1 (es) Receptores de union a antigeno mejorados
BR112017019217A2 (pt) peptídeos e combinações de peptídeos para uso em imunoterapia do câncer de pâncreas e outros cânceres
BR112017027639A2 (pt) epítopos celulares e combinações de epítopos celulares para emprego na imunoterapia de mieloma e outros cânceres
BR112018007206A2 (pt) peptídeos e combinações de peptídeos para uso em imunoterapia contra leucemia linfocítica crônica (cll) e outros cânceres
BR112018003460A2 (pt) peptídeos, combinações de peptídeos e suportes para emprego na imunoterapia de diversos cânceres
BR112017019804A2 (pt) peptídeos e combinações de peptídeos e arcabouços para uso na imunoterapia contra o carcinoma de células renais (ccr) e outros cânceres
BR112017017560A2 (pt) peptídeos e combinações de peptídeos para uso em imunoterapia do câncer de pulmão, incluindo cpcnp e outros câncere
EA201792084A1 (ru) Способы и композиции, связанные с полипептидами - агонистами gpcr
EA202192024A1 (ru) Рецепторы, обеспечивающие прицельную костимуляцию, для адоптивной клеточной терапии
BR112018075649A2 (pt) anticorpos anti-b7-h3 e conjugados de fármaco de anticorpo
EA202090757A1 (ru) T-КЛЕТОЧНЫЕ РЕЦЕПТОРЫ, РАСПОЗНАЮЩИЕ МУТАНТНЫЙ p53
BR112019011065A2 (pt) métodos para determinação da dosagem de células t car